Cost-savings and health impact of strategies for prevention of Respiratory Syncytial Virus with nirsevimab in Chile based on the integrated analysis of 2019–2023 national databases... by Denis Sauré, Miguel O’Ryan, Juan Pablo Torres, Natalia Trigo, Gonzalo Diaz, Marcel Goic, Charles Thraves, Jorge Pacheco, Patricio Aguilera, Andrea Caro, Leonardo J. Basso

Subjects: Get full text

Therapeutic proteins immunogenicity: a peptide point of view by Feliciana Real-Fernandez, Fosca Errante, Andrea Di Santo, Anna Maria Papini, Paolo Rovero

Subjects: Get full text

The Holy Grail: highlighting the need for equitable access to dementia treatments and clinical trials by Rebekah M. Ahmed, Olivier Piguet, Catherine J. Mummery, Sharon L. Naismith, Muireann Irish

Subjects: Get full text

Reflections on COVID-19: A Literature Review of SARS-CoV-2 Testing by Chin Shern Lau, Helen M. L. Oh, Tar Choon Aw

Subjects: Get full text

Highly-Sensitive Polymer Optical Fiber SPR Sensor for Fast Immunoassay by Ying Wang, Xing Rao, Xun Wu, George Y. Chen, Changrui Liao, Mateusz Jakub Smietana, Yiping Wang

Subjects: Get full text

Dataset of SARS-CoV-2 spike protein receptor binding domain variants in complex with antigen-binding fragments targeting COVID-19 vaccine-referenced variantsModel Archive by Ferdinando Spagnolo, Florigio Lista, Claudia Curcio

Subjects: Get full text

Characterization of Vaccine-Enhanced Humoral Immune Responses Against Emergent SARS-CoV-2 Variants in a Convalescent Cohort by Jared Sheehan, Amber J. Trauth, Michael E. Hagensee, Alistair J. Ramsay

Subjects: “…convalescent serum IgG and IgA antibodies…”
Get full text

Towards an HCV vaccine: an overview of the immunization strategies for eliciting an effective B-cell response by Gabriel L. Costa, Giuseppe A. Sautto

Subjects: Get full text

Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity by Dafei Chai, Junhao Wang, Jing Ming Lim, Xiaohui Xie, Xinfang Yu, Dan Zhao, Perry Ayn Mayson Maza, Yifei Wang, Dana Cyril-Remirez, Ken H. Young, Yong Li

Subjects: Get full text

Development of an mPBPK machine learning framework for early target pharmacology assessment of biotherapeutics by Krutika Patidar, Nikhil Pillai, Saroj Dhakal, Lindsay B. Avery, Panteleimon D. Mavroudis

Subjects: “…Target pharmacology, Antibodies, Pharmacokinetics, High-throughput ML, Decision tree classification.…”
Get full text

Erenumab effectiveness and safety: comparison of real-life data and clinical trial results by Austėja Dapkutė, K. Ryliškienė

Subjects: Get full text

Identification of plasma proteins binding oxidized phospholipids using pull-down proteomics and OxLDL masking assay‡ by Philipp Jokesch, Lisa Holzer, Lydia Jantscher, Sebastian Guttzeit, Rudolf Übelhart, Olga Oskolkova, Valery Bochkov, Bernd Gesslbauer

Subjects: Get full text

Seroprevalence of IgM/IgG and Neutralizing Antibodies against SARS-CoV-2 in Unvaccinated Young Adults from Mexico Who Reported Not Having Had a Previous COVID-19 Infection by Diana Lourdes Padilla-Bórquez, Mónica Guadalupe Matuz-Flores, Jorge Hernández-Bello, Gabriela Athziri Sánchez-Zuno, Samuel García-Arellano, Edith Oregon-Romero, Melva Guadalupe Herrera-Godina, Guillermo González-Estevez, Norma Patricia Adan-Bante, Jesús Alfredo Rosas-Rodríguez, José Francisco Muñoz-Valle

“…A qualitative determination of anti-SARS-CoV-2 antibodies in serum was performed by lateral flow immunoassay (Certum IgG/IgM Rapid Test™ cassette kit) and neutralizing antibodies were also determined (GenScript cPass assay). …”
Get full text

More on the pathogenesis of thrombotic thrombocytopenic purpura. Comment on “Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism” and on “The different faces of thrombotic thrombocytopenic purpura” by Flora Peyvandi

Get full text

Technologically-Treated Polyclonal Affinity-Purified Antibodies to the Tumor Necrosis Factor-α, Brain Specific S-100 Protein and Histamine in Treatment of Functional Dyspepsia: Results of the Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial by Yu. O. Shulpekova, I. V. Maev, V. B. Grinevich, I. B. Khlynov, Yu. G. Shvarts, V. T. Ivashkin

Subjects: “…technologically-treated polyclonal affinity-purified antibodies to the tumor necrosis factor-α…”
Get full text

Emerging therapeutics in idiopathic inflammatory myopathy by Shinji Sato

Subjects: Get full text

Donor-derived cell-free DNA for detection of acute rejection in lung transplant recipients by Gökce Yavuz, Julia Walter, Julia Walter, Kaimo Hirv, Oliver Wachter, Andrea Dick, Julia Kovacs, Julia Zimmermann, Olaf M. Glueck, Maximilian Vorstandlechner, Nicole Samm, Jan M. Fertmann, Wulf Sienel, Sebastian Michel, Sebastian Michel, Michael Irlbeck, Nikolaus Kneidinger, Nikolaus Kneidinger, Nikolaus Kneidinger, Rudolf Hatz, Rudolf Hatz, Jürgen Behr, Jürgen Behr, Christian Schneider, Christian Schneider, Teresa Kauke, Teresa Kauke

Subjects: Get full text

Evaluation of veterinary laboratory proficiency based on results of interlaboratory comparisons organized by FGBI “ARRIAH” in 2018–2019 by A. Yu. Sukharkov, Z. B. Nikonova, O. P. Byadovskaya, A. S. Pershin, M. I. Shulpin, I. A. Chvala

Subjects: Get full text

Study of pathogenesis and immune response at experimental infection of broiler chicks with avian metapneumovirus subtype В by M. A. Volkova, P. S. Yaroslavtseva, V. Yu. Sosi Pato Rova, T. L. Eroshina, I. A. Chvala

Subjects: Get full text

CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression by Agapitos Patakas, Bochong Li, Naveen K Mehta, Kristan Meetze, Patrick A Baeuerle, Jennifer S Michaelson, Hannah M Findlay, Timothy B London

“…Background Despite significant progress in the development of T cell-engaging therapies for various B-cell malignancies, a high medical need remains for the refractory disease setting, often characterized by suboptimal target levels.Methods To address this issue, we have developed a 65-kDa multispecific antibody construct, CLN-978, with affinities tuned to optimize the killing of low-CD19 expressing tumor cells. …”
Get full text